Lonza’s Synaffix adds Boehringer and Mitsubishi Tanabe as ADC licensing partners
Lonza’s Synaffix has secured two separate licensing deals with Boehringer Ingelheim and Japanese drugmaker Mitsubishi Tanabe Pharma for its antibody-drug conjugate tech. The two “long-term” deals were...
View ArticleLeyden Labs gets $70M to test if nasal sprays can help protect against viruses
A Dutch biotech creating nasal sprays to protect against the flu and coronavirus has raised an additional $70 million and acquired a nimble Singapore startup to help with its mission. Leiden-based...
View ArticleVersant unveils Light Horse with $62M and a partnership with Novartis
Versant Ventures' latest biotech emerged on Thursday morning with a $62 million Series A from Bristol Myers Squibb, AbbVie and others, plus a partnership with Novartis that could be worth as much as $1...
View ArticleNumab extends its Series C; AnaCardio raises $19M for its heart failure drug
Plus, news about RheumaGen and RyboDyn: Numab Therapeutics brings in $55M: The Swiss biotech extended its Series C, originally disclosed in ...
View ArticleSamsung Bio extends ADC partnership; Veeda rebrands as CDMO
Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. Samsung Biologics has extended its collaboration with LigaChem...
View ArticleIs this the digital health M&A wave we’ve been expecting?
2025 is starting out strong with a couple of deals. The most notable is a tie-up between Glen Tullman’s Transcarent and Accolade, the health navigation company that was part of the wave of digital...
View ArticleAfter lackluster 2024, biopharma industry prays stalled M&A will finally move...
Biopharma leaders will descend on San Francisco next week hopeful that the industry’s biggest dealmaking event will finally yield some much sought-after M&A. The industry needs it after a slow...
View ArticleCell therapy startup A2 Biotherapeutics nets $80M Series C
A2 Biotherapeutics has raised $80 million to run three experimental CAR-T programs for solid tumor cancers. The biotech is developing what it calls logic-gated cell therapies, which it believes will...
View ArticleTenpoint reveals positive Phase 3 data for vision drug
Tenpoint Therapeutics’ presbyopia drug showed “significant improvements” in near vision and reading speed in a Phase 3 trial. The biotech said the results keep it on track for an FDA filing in the...
View ArticleCatalyst staves off Firdapse competition from Teva for a decade
Catalyst Pharmaceuticals' controversial $375,000 rare autoimmune disease drug now won't face generic competition from Teva until Feb. 25, 2035, thanks to a patent settlement announced by the two...
View ArticleBayer says elinzanetant quelled hot flashes in women undergoing cancer treatment
As Bayer awaits an FDA decision on its non-hormonal treatment for hot flashes caused by menopause, the company is unveiling new results in a slightly different patient population: women whose hot...
View ArticleIGM Biosciences’ autoimmune pivot lasts three months after interim data...
About three months ago, IGM Biosciences announced plans to stay afloat by focusing its resources on a clinical-stage autoimmune asset. Now the company is shelving the drug, laying off most of its...
View ArticleShoreline cuts staff as its partnership with Gilead's Kite is now in flux
Shoreline Biosciences, a gene editing and cell therapy biotech, has let go of staffers dedicated to a cell therapy project that's working with Gilead's Kite unit. Shoreline CEO Kleanthis Xanthopoulos...
View ArticleIntellia to cut workforce by 27%, targets 2027 commercial launch
Intellia Therapeutics is the latest CRISPR company resorting to layoffs as investors increasingly turn away from gene editing. The Cambridge, MA-based company announced Thursday that it would reduce...
View ArticleWith $120M, GSK-allied Ouro Medicines throws its hat into burgeoning TCE ring
T cell engagers are having a moment, much like antibody-drug conjugates have for the past two years. The cell-depleting medicines, known simply as TCEs, are being adopted from the oncology field as a...
View ArticleMarea reports early Phase 2 data for cholesterol-lowering drug it licensed...
Marea Therapeutics on Friday posted some encouraging results with its lead program, a triglyceride-lowering medicine for cardiovascular disease, that could give an indication of whether the investors...
View ArticleRepare pauses late-stage plans, reshuffles pipeline in effort to cut costs
Repare Therapeutics is slamming the brakes on its gynecologic cancer assets and prioritizing earlier-stage candidates as part of a series of changes designed to stretch its cash reserves. The biotech is
View ArticleLilly ventures into pulmonary fibrosis with startup Mediar
Boston-area startup Mediar Therapeutics is teaming up with Eli Lilly on a new drug for idiopathic pulmonary fibrosis. Lilly — one of the five large pharmas backing Mediar – will pay $99 million in...
View ArticleJohn Maraganore turns to ex-Alnylam colleague to lead his latest RNAi bet;...
→ City Therapeutics broke cover in October with a $135 million Series A and the opportunity for executive chairman John Maraganore to run it back with RNAi-based therapies. This week, the company ...
View ArticleAnother biotech scoops up asset from China-based Keymed and nabs $180M
Two biotechs emerged on Friday with assets from Keymed Biosciences, extending a proliferating trend of Western investors propping up new companies to further develop assets discovered or initially...
View Article